[CAS NO. 2083622-09-5] MBM-55
PRODUCTS SPECIFICATIONS [2083622-09-5]
DESCRIPTION [2083622-09-5]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 498.55 |
| Molecular Formula | C28H27FN6O2 |
| SMILES | NC(C(C=C1)=C(OCC2=CC=CC(F)=C2)C=C1C3=CN=C4N3C=CC(C5=CN(CCN(C)C)N=C5)=C4)=O |
Summary
MBM-55 is a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC 50 of 1 nM. MBM-55 shows a 20-fold or greater selectivity in most kinases with the exception of RSK1 ( IC 50 =5.4 nM) and DYRK1a ( IC 50 =6.5 nM). MBM-55 effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis . MBM-55 shows antitumor activities, and no obvious toxicity to mice [1] .
IC50 & Target
IC50: 1 nM (Nek2), 5.4 nM (RSK1), 6.5 nM (DYRK1a), 57 nM (CHK1), 91 nM (GSK-3β), 20 nM (ABL), 370 nM (CDK2), 441nM (CDK4), 608 nM (AKT1), 5300 nM (Aurora A) [1]
In Vitro
MBM-55 (compound 42g) inhibits MGC-803, HCT-116, Bel-7402 cells proliferation with IC
50
s of 0.53, 0.84, 7.13 μM, respectively
[1]
.
MBM-55 (0.5-1 μM; 24 hours) induces G2/M phase arrest and accumulation of cells with >4N content in HCT-116 cells
[1]
.
MBM-55 (0.5-1 μM; 24 hours) causes cell apoptosis in a concentration-dependent manner in HCT-116 cells
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Cycle Analysis [1]
| Cell Line: | HCT-116 cells |
| Concentration: | 0.5, 1 μM |
| Incubation Time: | 24 hours |
| Result: | Induced G2/M phase arrest and accumulation of cells with >4N content. |
Apoptosis Analysis [1]
| Cell Line: | HCT-116 cells |
| Concentration: | 0.5, 1 μM |
| Incubation Time: | 24 hours |
| Result: | Caused cell apoptosis in a concentration-dependent manner. |
In Vivo
MBM-55 (20 mg/kg; i.p.; twice a day for 21 days) exhibits good antitumor activity and a well-tolerated dose schedule in nude mice bearing HCT-116 xenografts
[1]
.
MBM-55 (1.0 mg/kg; i.v.) treatment shows the CL, V
ss
, T
1/2
, AUC
0-t
, and AUC
0-∞
values of 33.3 mL/min/kg, 2.53 L/kg, 1.72 hours, 495 ng/h/mL and 507 ng/h/mL, respectively.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Female BALB/c nu/nu mice (5-6 weeks, bearing HCT-116 xenografts) [1] |
| Dosage: | 20 mg/kg |
| Administration: | Intraperitoneal injection; twice a day for 21 days |
| Result: | Significantly suppressed tumor growth. |
| Animal Model: | Male Sprague Dawley (SD) rats [1] |
| Dosage: | 1.0 mg/kg |
| Administration: | IV injection (Pharmacokinetic Analysis) |
| Result: | The CL, V ss , T 1/2 , AUC 0-t , and AUC 0-∞ values were 33.3 mL/min/kg, 2.53 L/kg, 1.72 hours, 495 ng/h/mL and 507 ng/h/mL, respectively. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
DMSO : 125 mg/mL ( 250.73 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.0058 mL | 10.0291 mL | 20.0582 mL |
| 5 mM | 0.4012 mL | 2.0058 mL | 4.0116 mL |
| 10 mM | 0.2006 mL | 1.0029 mL | 2.0058 mL |